Navigation Links
New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia

--Study Used To Support FDA Approval of SEROQUEL XR--

WILMINGTON, Del., May 22, 2007 /PRNewswire-FirstCall/ -- AstraZeneca today announced that two analyses from a large-scale study that investigated the efficacy of SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets, a once-daily medicine for the treatment of schizophrenia in adult patients, were presented today at the annual meeting of the American Psychiatric Association (APA). These analyses from the clinical trial data for SEROQUEL XR showed that it was effective versus placebo in patients with an acute exacerbation of symptoms of schizophrenia.(1,2)

On May 17, 2007, the U.S. Food and Drug Administration (FDA) approved SEROQUEL XR for the treatment of schizophrenia in adult patients.

"Both analyses show that SEROQUEL XR was superior to placebo, demonstrating it is another viable treatment option for schizophrenia," said Charles Schulz, MD, Professor and Head, Department of Psychiatry, University of Minnesota Medical School. "These analyses are significant because SEROQUEL XR may provide greater convenience and simplicity in patient treatment plans."

About large-scale study: Study 132

This six-week, double-blind, randomized, placebo-controlled study investigated the efficacy and safety of once-daily SEROQUEL XR. In this study, 588 patients with acute schizophrenia were randomized to receive either SEROQUEL XR at 400, 600, or 800 mg/day, the immediate release formulation of SEROQUEL(R) (quetiapine fumarate) at 400 mg/day (200 mg twice-daily), or placebo. The primary endpoint was assessed using the Positive and Negative Syndrome Scale (PANSS)(+).(1,2)

In the study, SEROQUEL XR was generally well-tolerated. SEROQUEL XR was administered once-daily at fixed doses, with dose escalation conducted over the initial three days (Day 1 = 300mg, Day 2 = 400 or 600mg, and Day 3=400, 600 or 800mg). The immediate release formul
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/26/2015)... 26, 2015  PAREXEL International Corporation (NASDAQ: PRXL ... the Goldman Sachs Healthcare Conference in Palos Verdes, CA.  ... Officer, will be making a presentation on PAREXEL and ... June 9, 2015. A live webcast of ... of PAREXEL,s website at www.PAREXEL.com in the ...
(Date:5/26/2015)... 26, 2015 Cellular testing ... ,What,s the future of technologies for screening cells? ... 2015. Stay ahead there for data, benefiting your ... results, R&D, opportunities and revenue forecasts. ... you what,s possible for cell-based assays ...
(Date:5/26/2015)... -- ViiV Healthcare, Aurobindo Pharma, and the ... Aurobindo Pharma has submitted an Abbreviated New Drug Application ... Food and Drug Administration (FDA), for the treatment of ... version of dolutegravir, less than two years after FDA ... the United States . Upon receiving ...
Breaking Medicine Technology:PAREXEL International To Present At Goldman Sachs Healthcare Conference 2Cell-Based Assays: World Industry and Market Prospects 2015-2025 2Cell-Based Assays: World Industry and Market Prospects 2015-2025 3Cell-Based Assays: World Industry and Market Prospects 2015-2025 4Cell-Based Assays: World Industry and Market Prospects 2015-2025 5Cell-Based Assays: World Industry and Market Prospects 2015-2025 6Cell-Based Assays: World Industry and Market Prospects 2015-2025 7ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 2ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 3ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 4ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 5ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 6ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 7
...   Prasco® Laboratories announced today it has entered into ... ) for the distribution in the U.S. of ... (Carbamazepine) Extended-Release Capsules in 100 mg, 200 mg and ... are AB-rated, therapeutically equivalent and substitutable for the brand ...
... 2012  The Board of Directors of MiMedx Group, Inc. (OTCBB: ... supports the Company,s Chairman and CEO, Parker H. "Pete" ... Exchange Commission ("SEC"). The SEC has ... in 2007, when he was Chairman and CEO of ...
Cached Medicine Technology:Prasco® Launches Authorized Generic of Shire's Carbatrol® 2Prasco® Launches Authorized Generic of Shire's Carbatrol® 3Prasco® Launches Authorized Generic of Shire's Carbatrol® 4MiMedx Group, Inc. Board Announces Support for Chairman Parker H. "Pete" Petit 2
(Date:5/26/2015)... Phoenix, AZ (PRWEB) May 26, 2015 Beloved ... its innovative sixty minutes or less drain clog guarantee or ... discounts all of which can be found here . ... which has played no small part in the company’s rich ... less drain clog guarantee covers every drain clog imaginable. Whether ...
(Date:5/26/2015)... Now offering innovative, safe, and effective hair ... Dr. Hedi Belajouza in Tunisia extends the boundaries ... the last detail — meticulous hair placement, artistic shape ... harvested follicle — are all results in exceptionally satisfied ... the artistry and talent of Tunisian hair transplant surgeon, ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Sexual harassment and ... Title IX is best known for creating opportunities in women's ... for sexual assault response and prevention. In a recent episode ... Global Sports Advocates explains what Title IX means for ... get in front of this issue to protect students. , ...
(Date:5/26/2015)... 26, 2015 Irwin Gross, M.D., ... a hospital-wide Patient Blood Management (PBM) initiative at Eastern ... blood usage by more than 60 percent and improved ... in detail in an article in the May 2015 ... reduced perioperative red cell loss, less acute kidney injury ...
(Date:5/26/2015)... Angeles, CA (PRWEB) May 26, 2015 ... Center recently joined Dr. Marissa Pei on ... union” conversation focusing on addiction. Aired on KCAA AM ... and Deena Duncan, marriage and family therapist, as they ... is estimated to affect more than 23.5 million Americans. ...
Breaking Medicine News(10 mins):Health News:Parker and Sons Offers Special, Sixty Minute Drain Clean Guarantee or Else It’s on Them 2Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 2Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 3Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 4Health News:Paul Greene Explores Title IX and College Sports on SCI TV 2Health News:Paul Greene Explores Title IX and College Sports on SCI TV 3Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 3Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 2Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 3
... (TSXV:MFS) announced that positive clinical results when using the ... the treatment of early stage breast cancer tumors, were ... the Toronto Stock Exchange on March 25, 2009 and ... held March 14-18, 2009 in Las Vegas, Nevada. The ...
... Pleads Guilty to Felony Misbranding WASHINGTON, April 15 ... Institute Diagnostics (NID), have entered into a global ... and civil claims concerning various types of diagnostic ... to laboratories throughout the country until 2006, the ...
... Program Use Vary in EffectivenessWASHINGTON, April 15 ... benefit programs, companies continue to add wellness and ... their workers. Additionally, companies are finding greater success ... these programs, according to a survey by Watson ...
... ability to diagnose the disease, , , WEDNESDAY, April ... could help improve the tracking of changes in ... University School of Medicine. , The technology uses ... of features in or on a single cell. ...
... 2009 -- Sleep is such an essential part of human ... doing it -- some more successfully than others. Sleep disorders ... are a major cause of disease and injury. People who ... attack, stroke, hypertension, obesity, depression, and accidents. Nearly a fifth ...
... April 15 On April 1, 2009, Hospices around ... all those individuals that volunteer in Hospice. The ... Administrative Volunteer, Patient Care Volunteer and Lifetime Achievement. ... a Visionary Award Winner (an individual not directly connected ...
Cached Medicine News:Health News:Medifocus Inc. Reports Improved Clinical Efficacy for its Phase II, Randomized Clinical Study for the Treatment of Early Stage Breast Cancer Tumors 2Health News:Medifocus Inc. Reports Improved Clinical Efficacy for its Phase II, Randomized Clinical Study for the Treatment of Early Stage Breast Cancer Tumors 3Health News:Quest Diagnostics to Pay U.S. $302 Million to Resolve Allegations That a Subsidiary Sold Misbranded Test Kits 2Health News:Quest Diagnostics to Pay U.S. $302 Million to Resolve Allegations That a Subsidiary Sold Misbranded Test Kits 3Health News:Quest Diagnostics to Pay U.S. $302 Million to Resolve Allegations That a Subsidiary Sold Misbranded Test Kits 4Health News:Companies Continue To Add Wellness Programs, Watson Wyatt/National Business Group On Health Survey Finds 2Health News:Companies Continue To Add Wellness Programs, Watson Wyatt/National Business Group On Health Survey Finds 3Health News:New way to analyze sleep disorders 2Health News:New way to analyze sleep disorders 3
Cold light source triple outlet....
Cold light source single outlet....
The 9100 is a truly affordable 100 Watt xenon light source providing accurate color and brightness. This xenon light source is ideal for surgery centers, evaluations or general office use....
The Carl Zeiss Head-worn Loupes L and LC are the ideal solution if a low magnification suffices for your work and you want to keep your hands free to perform the task at hand....
Medicine Products: